Eltek Ltd. $ELTK

Historic Volumes for Eltek Ltd. (NASDAQ:ELTK)

Eltek Ltd. (NASDAQ:ELTK)

Eltek Ltd. (NASDAQ:ELTK) shares jumped over 50% after the company released news that it had received a $3 million project order from a governmental authority. Volumes approached historic levels. The thinly traded shares have a listed 30-day, daily average volume figure of less than 6,500 shares traded per day. However today, after the news hit the market, over 6.3 million shares traded on the NASDAQ.

The project covers a two year period and Eltek Ltd. (NASDAQ:ELTK) will be required to meet quarterly milestones. The government has an option to extend the project for an additional year. If the option is picked up, Eltek will be required to meet additional quarterly milestones. Quarterly payments to Eltek Ltd. (NASDAQ:ELTK) will be subject to the fulfillment of each milestone. The project is expected to generate total aggregate revenues of approximately $2.1 million (approximately $3 million if the option is exercised).

Mr. Yitzhak Nissan, Chairman of the Board and Chief Executive Officer, “The selection of Eltek by this customer attests to the trust in the Company’s technological capabilities. We believe that this order will advance our competitiveness and brings us a step closer to increasing the number of orders from this customer and from additional costumers that value the quality and high reliability of our printed circuit boards”.

Eltek Ltd. (NASDAQ:ELTK) is a global manufacturer and supplier of technologically advanced solutions in the field of printed circuit boards (PCBs), and is the Israeli leader in this industry. PCBs are the core circuitry of most electronic devices. Eltek specializes in the manufacture and supply of complex and high-quality PCBs, HDI, multilayered and flex-rigid boards for the high-end market. Eltek has ITAR, AS-9100 and NADCAP Electronics permits and its customers include top of the line companies in the defense, aerospace and medical industries in Israel, the United States, Europe and Asia.

The customer may terminate the project on its first anniversary, but will be required to reimburse Eltek for its direct costs and expenses with regard to the project until such termination.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ELTK and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

More Positive News from NeuroDerm Ltd. (NASDAQ:NDRM)

NeuroDerm Ltd.(NASDAQ:NDRM)

NeuroDerm Ltd. (NASDAQ:NDRM) shares gapped up to open Wednesday trading. NDRM ended Tuesday at $23.15 then gapped up to open at $26.50 before hitting their inter-day high of $29.75. Trading has been over ten times the average daily volumes. The spike centered on news that the company’s lead product candidate, ND0612, has met it primary and key endpoints.

NeuroDerm Ltd. (NASDAQ:NDRM) is developing a drug for Parkinson’s Disease (PD). Parkinson’s Disease is a chronic and progressive disease of the central nervous system. It affects more than 10 million individuals worldwide. NeuroDerm Ltd. (NASDAQ:NDRM)’s ND0612H is designed to deliver steady subcutaneous doses of levodopa/carbidopa via a belt pump to PD patients with inadequately controlled motor fluctuations.

When a PD patient has an “OFF” episode, the PD patients is unable to perform routine activities like eating, bathing or dressing, is believed to happen when dopamine levels in the brain fall below a certain threshold. The subcutaneous doses of levodopa/carbidopa are thought to keep dopamine at levels which keeps the patient ON, or able to function normal routine activities. Levodopa, which is converted to dopamine in the brain, is a commonly prescribed drug for the treatment of Parkinson’s disease.

The patients in the group study receiving ND0612H experienced a statistically significant reduction in daily “OFF” time from baseline to day 28. Specifically, daily “OFF”” time was reduced by almost 51% from 5.5 hours to 2.7 hours (p=0.004) in the regimen 1 cohort (24-hour administration of ND0612H at a high day rate for 18 hours and low night rate for six hours). The 38 enrolled subjects had typical characteristics for patients with advanced Parkinson’s disease including: an average age of 63.5 years, 11.5 years since diagnosis and an average baseline OFF-time of 5.3 hours per day.

NeuroDerm Ltd. (NASDAQ:NDRM)  is the first to develop liquid levodopa (LD), the gold standard treatment for Parkinson’s disease, thus enabling for the first time continuous sub-cutaneous administration of this drug.

3/1/2017
Ticker Symbol NDRM
Last Price a/o 2:33 PM EST  $                    27.50
Average Volume                    187,400
Market Cap (mlns)  $                  607.22
Sales (mlns) $0.00
Shares Outstanding (mlns) 26.23
Share Float (mlns) 15.75
Shortable Yes
Optionable Yes
Inside Ownership 52.73%
Short Float 3.54%
Short Interest Ratio 2.98
Quarterly Return 31.91%
YTD Return 4.28%
Year Return 90.07%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Worth the Risk?

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)

Israel-based XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company has two product candidates in clinical development. The first is CDR1 peptide is a novel compound, working via a novel mechanism of action, for the treatment of Systemic Lupus Erythematosus (“SLE”). hCDR1 has completed three clinical trials involving more than 400 patients. Recombinant Erythropoietin (rHuEPO) is a known compound the company is developing for the prolongation of multiple myeloma (MM) advanced-stage patients’ survival and improvement of their quality of life.

History

On January 5th, 2017 XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) announced that new in-vitro data from studies evaluating cells obtained from serum samples of patients with Sjögren’s syndrome demonstrate that incubation with hCDR1 resulted in a significant reduction of gene expression of three cytokines considered to be pathogenic in Sjögren’s syndrome.

On January 25th, 2017 the company announced a change in the ratio from one depositary share (DS) representing twenty ordinary shares to a new ratio of one DS representing one hundred ordinary shares. For the Company’s DS holders, this ratio change would have the same effect as a reverse split on the XTL DSs on the basis of one (1) new DS for every five (5) old DSs held.

On February 13, 2017 XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) announced that two leading experts in  rheumatology, Robert  Fox,  MD  and  Simon  Bowman,  MD,  joined  the Company’s  clinical  advisory board  to  help  guide  a planned  Phase  II  trial to  evaluate  the company’s investigational drug, hCDR1, for the treatment of Sjögren’s syndrome.

The Numbers

One year ago XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) was trading at $6. Today XTLB shares closed at $3.58. The company has no sales or earnings. HC Wainwright is the only firm that covers XTLB and rates the shares as a “Strong Buy”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Update – MySize, Inc. (Nasdaq: MYSZ) Doubles in Inter-Day Trading!

My Size, Inc. – Nasdaq: MYSZ

UPDATE 12:57 PM EST – NASDAQ:MYSZ shares have gained over 100% on very heavy volumes. The Israeli-based APP company ended Friday’s trading at $3.85 and has reached a high today of $10.90 before setting back to just under $8.

SNU’s original article published before the opening bell today:

Israeli-based My Size Inc. (Nasdaq: MYSZ) is a novel approach to a problem shares by both consumers and online retailers – accurate measurements. My Size Inc. (Nasdaq: MYSZ) is the developer and owner of MySizeID and SizeUp DIY. While shopping online, the founders were frustrated with the “hit or miss” fit of different brands, and this frustration was augmented by the return process – a frustration not only shared by online retailers but also monetized in their operational expenses.

MySizeId lets consumers use their smartphone APP to create a secure, online profile of their personal measurements, which can then be utilized with partnered online retailers to ensure that no matter the manufacturer or size chart, they will always get the right fit. For online retailers, MySizeID offers a solution that can potentially reduce returns from online purchases, which will in turn, increase margins and ultimately result in higher brand loyalty.

SizeUp DIY is a smartphone APP that allows the user to use their smartphone to measure across any flat surface. The new technology enables users to instantly and accurately measure just about any object, flat surfaced or otherwise, by moving their Smartphone, in the air, from the starting point to the end-point of an object. Measurements can be taken in either inches or centimeters.

My Size Inc. (Nasdaq: MYSZ) started trading in 2016, but MYSZ shares have seen virtually no real volume until recently – less than 150,000 shares traded so far in February. Last week, MYSZ fell from $5.12 to $4.46 and Friday MYSZ closed at $3.85. Given the light volume and the price action, this could represent a real opportunity for investors that want in early on a stock that could impact an entire consumer sector and that solves a real issue for both consumers and online retailers.

Reports place five-year growth estimates for My Size Inc. (Nasdaq: MYSZ) at 25% which is considered impressive in an industry that some calculate has a growth estimate of less than 1%.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

MySize Inc. (Nasdaq: MYSZ) Begins Trading

My Size, Inc. – Nasdaq: MYSZ

Israeli-based My Size Inc. started trading today under the ticker MYSZ. The idea for MySizeID is the brainchild of the company’s founders. While shopping online for clothes, they were frustrated with the “hit or miss” fit of different brands, and this frustration was augmented by the return process.

MySizeId lets consumers create a secure, online profile of their personal measurements, which can then be utilized with partnered online retailers to ensure that no matter the manufacturer or size chart, they will always get the right fit. For online retailers, MySizeID offers a solution that can potentially reduce returns from online purchases, which will in turn, increase margins and ultimately result in higher brand loyalty.

MYSZ has trade between $5.68 and $6.51 on volumes exceeding 70,000. Reports place five-year growth estimates for MySize, Inc. at 25% which is considered impressive in an industry that has a growth estimate of less than 1%.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.